KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Goodwill (2022 - 2025)

Historic Goodwill for Halozyme Therapeutics (HALO) over the last 4 years, with Q3 2025 value amounting to $416.8 million.

  • Halozyme Therapeutics' Goodwill changed 0.0% to $416.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $416.8 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $416.8 million for FY2024, which is 0.0% changed from last year.
  • Per Halozyme Therapeutics' latest filing, its Goodwill stood at $416.8 million for Q3 2025, which was down 0.0% from $416.8 million recorded in Q2 2025.
  • Halozyme Therapeutics' Goodwill's 5-year high stood at $416.8 million during Q2 2023, with a 5-year trough of $199.5 million in Q2 2022.
  • For the 4-year period, Halozyme Therapeutics' Goodwill averaged around $385.2 million, with its median value being $416.8 million (2023).
  • Per our database at Business Quant, Halozyme Therapeutics' Goodwill soared by 10895.27% in 2023 and then changed by 0.0% in 2024.
  • Over the past 4 years, Halozyme Therapeutics' Goodwill (Quarter) stood at $409.0 million in 2022, then grew by 1.9% to $416.8 million in 2023, then changed by 0.0% to $416.8 million in 2024, then changed by 0.0% to $416.8 million in 2025.
  • Its Goodwill stands at $416.8 million for Q3 2025, versus $416.8 million for Q2 2025 and $416.8 million for Q1 2025.